Sangeetha Venugopal

Assistant professor

Sylvester Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sangeetha Venugopal is an Assistant Professor at the Sylvester Comprehensive Cancer Center in the United States. Her research primarily focuses on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with recent publications addressing drug development, clinical outcomes, and innovative treatment approaches for these conditions. She is actively engaged in exploring the efficacy of various therapeutic agents, including hypomethylating agents and venetoclax, in high-risk patient populations.

Articles (15)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Hussein A. Abbas

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ghayas C. Issa

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Rashmi Kanagal Shamanna

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Sanam Loghavi

UNITED STATES

View details

Sunil Iyer

Columbia University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sangeetha Venugopal

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Azacitidine and venetoclax for HR-MDS: election results pending

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia

Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

Therapy-related myelodysplastic syndromes and acute myeloid leukemia

Drug development in higher-risk myelodysplastic syndromes

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress

Olutasidenib: from bench to bedside

Raising the bar for lower-risk myelodysplastic syndromes.

Trying to outRun-DIC in KMT2Ar AML: It's tricky.

A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy.

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.

Collaborators (5)

Hussein A. Abbas

Ghayas C. Issa

Rashmi Kanagal Shamanna

Sanam Loghavi

Sunil Iyer

Make your next move.